Clinical Trial Update: PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating frontline immunochemotherapy for primary mediastinal large B-cell lymphoma using antibody therapy combined with a checkpoint inhibitor.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mediastinal Large B-cell Lymphoma

Drugs mentioned

• Antibody therapy
• Checkpoint inhibitor

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Phase 2 | Status: RECRUITING